RAPP

Rapport Therapeutics Stock Analysis

AI Rating

Good
  • Quality5/10
  • Growth↓ 4/10
  • Value↑ 6/10
Rapport Therapeutics sales and earnings growth
RAPP Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 24.34%
  • FCF Y/Y↓ -31.02%
Rapport Therapeutics gross and profit margin trends
RAPP Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Rapport Therapeutics net debt vs free cash flow
RAPP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Rapport Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗